Oxford University spinout Vaccitech raised £ 20 million ( $ 27 m ) through Series A funding from GV and Sequoia China , along with existing investor Oxford Sciences Limited and Neptune Ventures . The funds will enable Vaccitech to expand its business , develop its lab structure and push its products , including a universal influenza vaccine and a breast cancer therapeutic in development . Vaccitech CEO , Tom Evans , said that the company is much faster at bringing its products to the market than most , because it is in Phase II of clinical trials for the flu and prostate cancer vaccines .
Oxford University spinout Vaccitech raised £20m ($27m) through series A funding from GV and Sequoia China, along with existing investor Oxford Sciences Innovation and Neptune Ventures. The funds will enable Vaccitech to expand its business, develop its lab structure and push its products, including a universal influenza vaccine and a prostate cancer therapeutic in development. Vaccitech CEO, Tom Evans, said that the company is much faster at bringing its products to the market than most, because it is in phase II of clinical trials for the flu and prostate cancer vaccines.